Myeloid-derived suppressor cells are involved in lysosomal acid lipase deficiency-induced endothelial cell dysfunctions by Zhao, Ting et al.
Myeloid-Derived Suppressor Cells Are Involved in Lysosomal
Acid Lipase Deficiency-Induced Endothelial Cell Dysfunctions
Ting Zhao*, Xinchun Ding*, Hong Du*,†, and Cong Yan*,†,‡
*Department of Pathology and Laboratory Medicine, Indiana University School of Medicine,
Indianapolis, IN 46202
†IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN 46202
‡Center for Immunobiology, Indiana University School of Medicine, Indianapolis, IN 46202
Abstract
The underlying mechanisms that lysosomal acid lipase (LAL) deficiency causes infiltration of
myeloid-derived suppressor cells (MDSCs) in multiple organs and subsequent inflammation
remain incompletely understood. Endothelial cells (ECs), lining the inner layer of blood vessels,
constitute barriers regulating leukocytes transmigration to the site of inflammation. Therefore, we
hypothesized that ECs are dysfunctional in LAL-deficient (lal−/−) mice. We found that Ly6G+
cells transmigrated more efficiently across lal−/− ECs than wild-type (lal+/+) ECs, which was
associated with increased level of platelet endothelial cell adhesion molecule-1 (PECAM-1) and
monocyte chemoattractant protein-1 (MCP-1) in lal−/− ECs. In addition, lal−/−ECs showed
enhanced migration and proliferation, decreased apoptosis, but impaired tube formation and
angiogenesis. lal−/− ECs also suppressed T cell proliferation in vitro. Interestingly, lal−/− Ly6G+
cells promoted in vivo angiogenesis (including a tumor model), EC tube formation and
proliferation. Finally, the mammalian target of rapamycin (mTOR) pathway was activated in lal−/−
ECs, and inhibition of mTOR reversed EC dysfunctions, including decreasing Ly6G+ cell
transmigration, delaying migration, and relieving suppression of T cell proliferation, which was
mediated by decreasing production of reactive oxygen species (ROS). Our results indicate that
LAL regulates EC functions through interaction with MDSCs and modulation of the mTOR
pathway, which may provide a mechanistic basis for targeting MDSCs or mTOR to rejuvenate EC
functions in LAL-deficiency related diseases.
Introduction
Lysosomal acid lipase (LAL) hydrolyzes cholesteryl esters and triglycerides in the lysosome
of cells to generate free fatty acids and cholesterol. LAL deficiency has been reported to
result in pulmonary inflammation, which is associated with neutrophil infiltration, increases
of foamy macrophages and alternation of proinflammatory cytokines/chemokines (1, 2).
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Endothelial cells (ECs), which play a crucial role in regulating blood flow, controlling
vessel-wall permeability, and quiescing circulating leukocytes, are both active participants
and regulators of inflammatory processes at a site of inflammation (3). Failure of ECs to
adequately perform their functions constitutes endothelial cell dysfunction. In LAL-deficient
(lal−/−) mice, whether LAL deficiency-induced myeloid lineage cell infiltration is related to
EC dysfunctions has not been studied yet.
Myeloid-derived suppressor cells (MDSCs), characterized by the co-expression of myeloid-
cell lineage differentiation markers Ly6G and CD11b, are a heterogeneous population of
immature myeloid cells, whose accumulation is associated with multiple pathological
conditions (4-6). Recent studies addressed the roles of tumor-associated MDSCs in the
interplay between immune suppression and angiogenesis, showing that angiogenic factors
produced by MDSCs facilitated EC angiogenic functions (7-9). We previously reported that
the neutral lipid metabolic pathway controlled by LAL plays a critical role in the
development and homeostasis of MDSCs, and have demonstrated that LAL deficiency led to
the infiltration and accumulation of MDSCs in various tissues of the mice, such as the lung,
spleen, thymus, liver and small intestine (10-12). lal−/− MDSCs possess both immune
suppressive function and tumor stimulatory function (13, 14). However, little is known
about whether and how MDSCs influence EC functions during LAL deficiency.
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that
regulates cell growth, proliferation, motility, survival, protein synthesis, and transcription in
response to growth factors and mitogens (15). In ECs, mTOR acts as a regulatory kinase,
playing an important role in EC survival, migration, and proliferation (16). We have recently
demonstrated that in lal−/− mice, the mTOR pathway was over-activated in bone marrow-
derived MDSCs (17). However, it is unknown whether the mTOR pathway is overly
activated in lal−/− ECs, and whether over-activation of this pathway is involved in EC
dysfunctions.
In the present study, EC functions in lal−/− mice, including transendothelial migration for
MDSCs and T cells, angiogenesis, and proliferation were determined. The ability of ECs in
regulating T cell proliferation and function was studied as well. Furthermore, the effects of
MDSCs on ECs were evaluated, focusing on MDSC transendothelial migration, EC
angiogenesis and proliferation. Finally, the mTOR pathway was investigated in lal−/− ECs.
Our study demonstrates for the first time that LAL deficiency results in EC dysfunctions
through interaction with MDSCs and over-activation of the mTOR pathway. Overproduction
of reactive oxygen species (ROS) is one of mediators involved in lal−/− EC dysfunctions.
These findings provide a mechanistic insight into LAL in controlling EC functions.
Materials and Methods
Animals
All scientific protocols involving the use of animals have been approved by the Institutional
Animal Care and Use Committee of Indiana University School of Medicine and followed
guidelines established by the Panel on Euthanasia of the American Veterinary Medical
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Association. Animals were housed under Institutional Animal Care and Use Committee-
approved conditions in a secured animal facility at Indiana University School of Medicine.
Isolation and in vitro culture of pulmonary ECs
ECs were isolated from lungs and cultured in vitro, based on published protocols with some
minor modifications (18, 19). Briefly, the mouse was anesthetized and 5 mL cold PBS was
injected via the right ventricle to flush the blood out. One milliliter of collagenase A (2
mg/mL, Roche, Indianapolis, IN, USA) was infused into the lung through the trachea. The
lung was removed and then incubated with 10 mL of collagenase A at 37°C for 30 min.
After the incubation, PBS was added to the tube, and the tube was vigorously shaken to
dissolve the lung. The resulting cell suspension was filtered through a 40 μm strainer and
centrifuged for 5 minutes at 1,500 rpm. After removal of the supernatant, the cell pellet was
subjected to magnetic bead sorting using anti-CD31 microbeads (Miltenyi Biotec., Auburn,
CA, USA) according to the manufacturer’s protocol. The resulting cells were plated onto
gelatin (Sigma-Aldrich, St. Louis, MO, USA)-coated six-well plates and maintained in
DMEM (Gibco, Grand Island, NY, USA) supplemented with endothelial cell growth
supplement, heparin, L-Glutamine (Sigma-Aldrich), fetal bovine serum (FBS), and
Antibiotic-Antimycotic (Gibco).
Isolation of bone marrow-derived MDSCs
MDSCs were isolated as we previously described (17, 20). Briefly, bone marrow cells were
isolated from the femurs and tibias of wild-type (lal+/+) and lal−/− mice. Cells were first
incubated with biotin-conjugated anti-Ly6G antibody (Miltenyi Biotec.) at 4°C for 15 min.
After washed with PBS, cells were incubated with anti-biotin microbeads (Miltenyi Biotec.)
at 4°C for another 15 min. Subsequently, cells were subjected to magnetic bead sorting
according to the manufacturer’s instructions (Miltenyi Biotec.). The resulting cells were
seeded into 96-well plates for further studies.
Isolation of bone marrow-derived macrophages
Macrophages were isolated based on a published protocol (21). Briefly, bone marrow cells
were harvested from lal+/+ and lal−/− mice. Cells were then cultured in DMEM/F12 medium
(Gibco) supplemented with 10% FBS and 50 ng/mL recombinant M-CSF (R&D,
Minneapolis, MN, USA). After 7 days’ culture, unattached cells were removed, and more
than 95% of remaining adherent cells were positive for F4/80 and CD11b by flow cytometry
analysis.
Transwell assay
Transwell assay was used to determine MDSC transendothelial migration. ECs were
collected by Accutase (Sigma-Aldrich) digestion. Around 5×104 cells in 250 μL media were
added to the upper chamber of 24-well 6.5-μm-pore Transwell plates (Corning, Corning,
NY, USA), while 500 μL media was placed in the lower chamber. Cells were incubated at
37°C, 5% CO2 for 48 h to form an EC monolayer. Then the supernatant was removed, and
CellTrackerTM Green 5-Chloromethylfluorescein Diacetate (CMFDA) (Invitrogen, Grand
Island, NY, USA)-labeled MDSCs (1×104 cells in 250 μL media) were added to the upper
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well. The media in the lower chamber was replaced with the same media as the upper
chamber. After 6 h, transendothelial migration of MDSCs was determined by counting their
numbers in the lower chamber under 5 random microscopic fields. For the neutralization
study, ECs were pretreated with 10 μg/mL neutralizing antibody against PECAM-1, MCP-1,
IL-6, TNF-α or control IgG for 1h.
Tube formation assay
The in vitro angiogenic activity of ECs was determined by matrigel tube formation assay as
previously described (22). Briefly, ECs were seeded at a density of 5×104 cells/well in 48-
well plates precoated with 150 μL/well growth factor-reduced matrigel (BD Biosciences,
San Jose, CA, USA). After 6 h of incubation, tube formation was observed with an inverted
microscope with image capture system (Nikon, Melville, NY, USA). Tube formation was
defined as a tube-like structure exhibiting a length four times its width (23). To detect the
effect of MDSCs on EC tube formation, MDSCs and ECs were co-cultured overnight.
Images of tube morphology were taken in 5 random microscopic fields per sample at × 40
magnification, and the cumulative tube lengths were measured by Image-Pro Plus software
(Media Cybernetics, Rockville, MD, USA).
In vitro wound healing assay
In vitro wound healing assay was performed to analyze EC migration as previously
described (24). Briefly, ECs were seeded at a density of 1.5×105 cells/well into a 24-well
plate and incubated overnight to form a confluent monolayer. Scratch was created by
scraping the cell monolayer in a straight line with a p200 pipet tip. After washing 3 times
with PBS, the medium was changed with DMEM containing 10% FBS and 5 μg/mL
mitomycin C (Sigma-Aldrich), and ECs were kept on culture at 37°C, 5% CO2. Images were
taken at 0 and 15 h after creating the scratch. Migration was estimated by measuring the
distances from one side of scratch to the other side using Image Pro-Plus software (Media
Cybernetics).
Small interfering RNA transfection
Before transfection, ECs were seeded into 6-well plates at a density of 2.5×105 cells/well
and incubated overnight. For small interfering RNA (siRNA)-mediated gene knockdown, 50
nmol/L of mTOR siRNA SMARTpool, platelet endothelial cell adhesion molecule-1
(PECAM-1, PECAM, CD31) siRNA SMARTpool, vascular endothelial growth factor
receptor 2 (VEGFR2) siRNA SMARTpool or control siRNA (Dharmacon, Chicago, IL,
USA) were transfected into cells with DharmaFECT Transfection Reagent IV (Dharmacon)
according to the manufacturer’s protocol. After 72 hours of transfection, cells were
harvested for further analysis.
Western blot analysis
Western blot analysis was performed as previously described (22). Briefly, ECs were lysed
in Cell Lytic MT lysis buffer (Sigma-Aldrich) with Protease Inhibitor Cocktail (Invitrogen)
for 15 minutes on a shaker. After centrifugation for 10 minutes at 12,000×g (4°C), the
supernatants were saved and protein concentrations of the samples were determined using
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the Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Equal amounts
of protein (30 μg) were loaded onto SDS-polyacrylamide gels and blotted onto PVDF
membranes (BioRad, Hercules, CA, USA). Western blots analysis used antibodies against
mTOR downstream S6, and p-S6 (rabbit monoclonal antibodies, 1:1,000, Cell Signaling,
Beverly, MA, USA), PECAM-1 (rabbit polyclonal anti-PECAM-1, 1:1,000, Abcam,
Cambridge, MA, USA) and intercellular adhesion molecule-2 (ICAM-2) (rabbit polyclonal
anti-ICAM-2, 1:200, Santa Cruz, Dallas, Texas, USA). Antibody against β-actin (rabbit
monoclonal anti-β-actin, 1:2,000, Cell Signaling) was used as a loading control. For
detection, the membrane was incubated with anti-rabbit IgG secondary antibodies
conjugated with horseradish peroxidase (1:2,000, Cell Signaling). Bands were visualized
using SuperSignal West Pico Chemiluminescent substrate (ThermoScientific Pierce,
Rockford, IL, USA).
Annexin V staining
Dual staining with FITC–annexin V and propidium iodide (PI) was performed to detect cells
undergoing apoptosis using an annexin V–FITC kit (BD Biosciences) as we described
previously (10). Single lung cells were first stained with endothelial marker CD31. After
washing with PBS, labeled cells were resuspended in annexin V-binding buffer containing
FITC-conjugated annexin V. PI was then added into cells and incubated on ice for 10 min.
Nonspecific binding was blocked by pre-incubating cells with rat IgG (10 mg/mL) and anti-
FcII/III. Cells were analyzed on a LSRII machine (Becton Dickinson, Franklin Lakes, New
Jersey, USA) within 1 h. Viable cells were defined by FITC– and PI– population. Early
apoptotic cells were defined by FITC+ and PI– population.
In vitro co-culture of ECs and MDSCs
ECs were resuspended and adjusted to density at 5×104 cells/mL. MDSCs after MACS
sorting were used immediately and the cell density was adjusted to 5×106 cells/mL. One
hundred microliters of MDSCs and 100 μL of ECs were mixed, and seeded into a well of
96-well plates. Seventy-two hours later, unattached MDSCs were removed by washing with
PBS, and the number of attached ECs was counted. Morphologically, MDSCs are much
smaller than ECs.
BrdU incorporation
Immunofluorescent staining of incorporated bromodeoxyuridine (BrdU) was also performed
on ECs after coculture with MDSCs for 3 days and washing off the MDSCs by PBS,
followed by flow cytometric analysis. BrdU incorporation was performed using the BrdU
Flow Kit (BD Biosciences) as we previously described (10). Briefly, BrdU was added to
cells at a final concentration of 10 μmol/L. One hour later, cells were collected and fixed.
After permeabilisation, cells were incubated with DNase I at 37°C for 1 h, followed by
labeling with anti-BrdU antibody for 20 min at room temperature. Cells were then analyzed
by flow cytometry.
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In vivo matrigel plug assay with ECs or MDSCs
This assay was performed according to established methods with minor modifications (25).
ECs or MDSCs were collected separately. After washed with PBS, 1×106 ECs or 2×106
MDSCs were centrifuged and resuspended in 40 μL PBS and mixed with 500 μL Matrigel
Basement Membrane Matrix (BD Biosciences) containing 15 units of heparin (Sigma-
Aldrich). The cell-matrigel-mixture was then injected subcutaneously into the abdomen of
3-month old lal+/+ mice. For the B16 melanoma tumor model, 1×106 MDSCs and 1×105
B16 melanoma cells were mixed in 500 μL matrigel, and then injected subcutaneously into
lal+/+ mice. After 10 days, the mice were sacrificed and plugs were harvested from
underneath the skin. The plugs were fixed, embedded, sectioned, stained with H&E, and
then examined using microscopy. To visualize capillaries, samples were
immunohistochemically stained with anti-CD31 antibody. For hemoglobin analysis, the
matrigel plugs were removed after 10 days and homogenized in 130 μL de-ionized water.
After centrifugation, the supernatant was harvested, and then used in the Drabkin assay
(Sigma-Aldrich) to measure hemoglobin concentration. Stock solutions of hemoglobin are
used to generate a standard curve. Results are expressed relative to total protein in the
supernatant.
T cell proliferation assay and lymphokine measurement by ELISA
CD4+ T cells were prepared and CFSE labeled as we previously described (26). Labeled
CD4+ T cells were co-cultured with ECs in 96-well plates pre-coated with anti-CD3
monoclonal antibody (mAb) (2 μg/mL) and anti-CD28 mAb (5 μg/mL) at 37°C, 5% CO2 for
4 d. The ratio of ECs/CD4+ T cells was 1:10. Proliferation of CD4+ T cells was evaluated as
CFSE dilution by FACS. The expression level of IL-4, IL-10, IFN-γ, and IL-17 in the
supernatants of the culture medium was measured using ELISA kits (BD Biosciences).
Real-time RT-PCR
Total RNAs from ECs or Ly6G+ cells were purified using the Qiagen total RNA purification
kit (Qiagen, Valencia, CA, USA). Quantitative (q)RT-PCR was performed as described
previously (20). Analysis was performed by the 2−ΔΔCT method. Primers of mMCP-1,
mCCR2, mIL-6, mTNF-α, VEGF and GAPDH for real-time PCR were described previously
(20).
Flow Cytometry Analysis
After 7 days of culture, ECs were harvested and washed with PBS. To detect VEGFR-2
expression level, cells were incubated with APC-conjugated anti-mouse VEGFR-2 antibody
(eBioscience, San Diego, CA, USA). For flow cytometry analysis, ≥10,000 cells were
acquired and scored using a LSRII machine (Becton Dickinson). Data were processed using
the CellQuest software program (Becton Dickinson).
ROS Measurement
The reactive oxygen species (ROS) level in ECs was measured by flow cytometry as we
previously described (13). Briefly, ECs were harvested, washed, and stained with 2 μmol/L
2′, 7′-dichlorofluorescein diacetate (Invitrogen) at 37°C for 30 min. After PBS wash, the
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ROS level was analyzed using a LSRII machine (Becton Dickinson). In a ROS inhibition
assay, the antioxidant N-Acetyl-L-cysteine (NAC) (Sigma-Aldrich) was added to ECs twice
per day for 3 days, followed by further analysis.
Statistics
Data were expressed as mean ± SD. Differences between two treatment groups were
compared by Student’s t-test. When more than two groups were compared, one-way
ANOVA with post-hoc Newman-Keul’s multiple comparison test was used. Results were
considered statistically significant when P < 0.05. All analyses were performed with
GraphPad Prism 5.0 (GraphPad, San Diego, CA, USA).
Results
LAL deficiency in ECs led to increased transendothelial migration of MDSCs
Transendothelial migration of leukocytes is a critical step in the inflammatory response,
during which ECs participate in regulating leukocyte transmigration from the vasculature to
the site of inflammation (27). Because we have previously reported that LAL deficiency
results in severe infiltration of MDSCs in multiple organs (1, 10, 12, 28, 29), the role of ECs
in MDSC infiltration was investigated. Transwell assay was performed to determine MDSC
transmigration across the endothelial monolayer formed by ECs isolated from lungs of lal+/+
or lal−/− mice. ECs were seeded into Transwell upper chambers and grown to confluence.
Freshly isolated bone marrow-derived Ly6G+ cells (MDSCs) from lal+/+ or lal−/− mice were
labeled with CMFDA and then loaded on the EC monolayers. In lal−/− mice, since almost all
Ly6G+ cells are positive for CD11b, which showed T cell suppression, Ly6G antibody was
used for purification of Ly6G+CD11b+ cells (30). Six hours later, the number of Ly6G+ cells
that had migrated to the lower chamber was counted. As shown in Figure 1A, when lal+/+
Ly6G+ cells were added to the EC monolayer, lal−/− ECs showed increased permeability,
with more Ly6G+ cells in the lower chamber, than that of lal+/+ ECs. In addition, we
repeated the experiments using lal−/− Ly6G+ cells to migrate across lal+/+ or lal−/− EC
monolayers, and there were more lal−/− Ly6G+ cells migrating to the lower chamber through
lal−/− ECs than lal+/+ ECs. These data suggest that 1) the increased permeability of lal−/−
ECs is a potential mechanism of increased Ly6G+ cell infiltration in the lal−/−mice and 2)
lal−/− Ly6G+ cells possess a stronger ability to transmigrate the pulmonary EC monolayer.
As a matter of fact, lal−/− Ly6G+ cell and lal−/− EC combination showed three times more
permeability than that of lal+/+ Ly6G+ cell and lal+/+ EC combination. In addition to Ly6G+
cells, lal−/− CD4+ T cells also showed increased ability of transendothelial migration, with
similar results as Ly6G+ cells (Figure 1B).
A number of adhesion molecules have been implicated in the process of leukocyte
transendothelial migration (27). It is plausible that increased expression of adhesion
molecules in lal−/− ECs facilitates Ly6G+ cell transmigration across the endothelial
monolayer. Among several tested proteins, Western blot analysis showed that expression of
PECAM-1 and ICAM-2 was both elevated in lal−/− ECs (Figure 1C). To assess functional
roles of PECAM-1 in ECs for Ly6G+ cell transendothelial migration, siRNA transfection
was performed to knockdown PECAM-1 expression in ECs. Results of Transwell assay
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showed that there were less migrated Ly6G+ cells in the groups of lal+/+ and lal−/− ECs with
PECAM-1 siRNA transfection than their counterparts with control siRNA transfection
(Figure 1D). Furthermore, ECs were treated with anti-PECAM-1 neutralizing antibodies. As
Figure 1E demonstrated, the transmigration of Ly6G+ cells across the EC monolayer was
reduced in the groups of ECs with anti-PECAM-1 antibody treatment compared to those
treated with control IgG. Taken together, increased expression of PECAM-1 in lal−/− ECs
contributed to enhanced Ly6G+ cell transmigration.
Moreover, chemokines secreted by ECs are crucial in recruiting monocytes into the vessel
wall, among which MCP-1 plays a major role (31, 32). In lal−/− ECs, the mRNA level of
MCP-1 was up-regulated by a Real-time PCR analysis (Figure 1F). Accordingly, expression
of MCP-1 receptor - CCR2 was increased in lal−/− Ly6G+ cells (Figure 1G). To examine
whether MCP-1 secreted by lal−/− ECs facilitated Ly6G+ cell migration, transwell study was
performed with ECs pre-treated with anti-MCP-1 neutralizing antibodies. As shown in
Figure 1H, fewer Ly6G+ cells transmigrated through ECs treated with anti-MCP-1 antibody
than those treated with control IgG. In addition, the mRNA levels of IL-6 and TNFα were
increased in lal−/− ECs (Figure 1F), both of which have been reported to be involved in EC
permeability (33, 34). After ECs were pre-treated with anti-IL-6 or anti-TNFα antibodies to
neutralize cytokines, Ly6G+ cell transmigration was not significantly inhibited. However,
combination of all three neutralizing antibodies (anti-MCP-1, anti-IL-6 and anti-TNFα
antibodies) showed a stronger blocking on Ly6G+ cell transmigration (Figure 1H).
Therefore, chemokines and cytokines, especially MCP-1, secreted by lal−/− ECs are
responsible for mediating Ly6G+ cell transendothelial migration.
LAL deficiency influenced EC angiogenic functions
Angiogenesis is a feature of chronic inflammation, a process ECs actively participate in (3).
Three studies were designed to assess angiogenic functions. Firstly, an important aspect of
angiogenesis involves the formation of capillary-like tubes by ECs (35). To determine
whether LAL deficiency influences tube formation, in vitro matrigel tube formation assay
was performed. As shown in Figure 2A, 6 h after seeding on matrigel, lal−/− ECs formed
significantly less completed and poorly connected tube networks than those of lal+/+ ECs.
Statistical results showed that there was more than 50% decrease in the total tube lengths in
lal−/− ECs compared with those of lal+/+ ECs, demonstrating that LAL deficiency impaired
EC tube formation in vitro. Interestingly, tube networks formed by lal−/− ECs showed a
delayed disappearance compared with those formed by lal+/+ ECs at 12h and 24h.
Secondly, we investigated the effect of LAL deficiency on EC-mediated in vivo
angiogenesis by in vivo matrigel plug assay. Fourteen days after subcutaneous injection of
EC-matrigel-mixture, the mice were sacrificed and plugs were harvested, sectioned, and
stained with H&E. The presence of capillaries in the matrigel was further detected by
immunohistochemical (IHC) staining with anti-CD31 antibody. Results showed that
administration of lal+/+ ECs induced formation of vessel-like structures and the presence of
erythrocytes were evidenced in the lumen (Figure 2B, see arrows), while administration of
lal−/− ECs led to formation of disorganized cell clusters, demonstrating that LAL deficiency
in ECs impaired their in vivo angiogenic function. As a control, plugs without ECs showed
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no vessel formation or CD31+ cells (data not shown), confirming that the above
observations were from extrinsic ECs. In addition, the hemoglobin content (a surrogate
marker of perfusion) was significantly lowered in the plugs mixed with lal−/− ECs (Figure
2C).
Thirdly, endothelial cell migration is an essential component of angiogenesis (36). To test
whether LAL deficiency in ECs affects their migration ability, we performed the in vitro
wound healing assay. ECs were treated with mitomycin C to eliminate the potential effects
of EC proliferation. As shown in Figure 2D, 15 h after creating the scratch, lal−/− ECs
demonstrated increased migration compared with that of lal+/+ ECs, evidenced by a
significant reduction in the wound area lacking cells. This indicates that LAL deficiency
facilitates EC migration.
LAL deficiency facilitated EC proliferation
Cell proliferation is essential for ECs to adequately perform their functions. Therefore, the
effect of LAL deficiency on EC proliferation was determined. CD31+ ECs from the lungs of
lal+/+ or lal−/− mice were isolated and counted. There were significantly more CD31+ cells
in the lungs of lal−/− mice than those in the lungs of lal+/+ mice (Figure 3A). When cultured
in vitro, lal−/− ECs demonstrated increased proliferation compared with that of lal+/+ ECs
(Figure 3B). The BrdU incorporation study further supported increased proliferation of
lal−/− ECs (Figure 3C). Since apoptosis may contribute to the numbers of ECs, we further
examined the apoptotic activity in isolated lung ECs by Annexin V staining. The percentage
of Annexin V positive cells in lung CD31+ cells was compared between lal+/+ and lal−/−
mice. As shown in Figure 3D, apoptosis in lal−/− lung CD31+ cells was decreased compared
with those of lal+/+ mice. The abnormality of lal−/− EC proliferation is a complicated
process, which can be influenced by environmental factors. In addition to the above intrinsic
defects in ECs, we also investigated the effect of blood plasma on EC proliferation. Plasma
was prepared from both lal+/+ and lal−/− blood, and added into culture medium (20%
plasma) of ECs. Seventy-two hours later, lal−/− plasma exerted a greater stimulatory effect
on both lal+/+ and lal−/− EC proliferation, compared with that of lal+/+ plasma (Figure 3E).
Since lal−/− ECs showed more sensitivity to plasma treatment, the potential mechanism
contributing to EC growth was investigated. VEGF has been found to have various functions
on ECs, the most prominent of which is the stimulation of proliferation and angiogenesis
(37, 38). The VEGF level was indeed increased in lal−/− plasma (data not shown).
Therefore, the level of its receptor VEGFR2 was examined in lal+/+ vs. lal−/− ECs. Flow
cytometry analysis showed that the expression level of VEGFR2 was increased in lal−/− ECs
(Figure 3F). After VEGFR2 knockdown in ECs, the stimulatory effect of lal−/− plasma on
EC proliferation was impaired (Figure 3G). These results indicate that both intrinsic defects
and environmental factors contribute to abnormal proliferation of lal−/− ECs.
LAL deficiency in ECs suppressed T cell proliferation
Increased T cell permeability across the ECs monolayer (Figure 1B) triggered us to further
investigate ECs’ effects on T cell proliferation and functions. ECs have been found to
function as antigen presentation cells, leading to activation of T cells (39, 40). We have
previously reported that LAL deficiency impaired T cell proliferation and function in lal−/−
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mice (26). Although the intrinsic defect and lal−/− MDSC suppression contribute to T cell
paucity (26), whether lal−/− ECs participate in T cell suppression has not been investigated.
CFSE-labeled lal+/+ CD4+ T cells were cultured in vitro and stimulated with anti-CD3 mAb
plus anti-CD28 mAb in the presence or absence of lal+/+ or lal−/− ECs for 4 d. Proliferation
of CD4+ T cells was evaluated by CFSC dilution (cell division). As demonstrated in Figure
4A, lal−/− ECs showed inhibition on proliferation of lal+/+ CD4+ T cells after anti-CD3 mAb
plus anti-CD28 mAb stimulation, whereas lal+/+ ECs had no effects on CD4+ T cell
proliferation. In the PBS control group, no proliferation was observed. Furthermore, the
secretion of CD4+ T lymphokines, e.g. IFN-γ (Th1), IL-4 and IL-10 (Th2) was also inhibited
by lal−/− ECs, while the secretion of Th17 lymphokine IL-17 remained unchanged (Figure
4B). Therefore, lal−/− ECs suppressed both T cell proliferation and lymphokine secretion.
Interaction with MDSCs leads to EC dysfunctions
Our previous publications have demonstrated that the MDSC population in lal−/− mice was
significantly increased in multiple organs (10-12). The synergism between Ly6G+ cells and
ECs in the lal−/− mice has been implicated in Figure 1A, in which not only lal−/− ECs had
enhanced permeability for Ly6G+ cells, but also lal−/− Ly6G+ cells had greater
transmigration capability than that of lal+/+ Ly6G+ cells. It is intriguing to determine if lal−/−
Ly6G+ cells influence EC proliferation and functions. To test whether Ly6G+ cells
contribute to angiogenesis, the EC tube formation assay was performed in the presence of
Ly6G+ cells. In this study, both lal+/+ and lal−/−Ly6G+ cells facilitated lal−/− EC tube
formation (Figure 5A). Despite impaired tube formation in the absence of Ly6G+ cells,
lal−/− ECs co-cultured with lal−/− Ly6G+ cells formed more complete tube networks than
those with lal+/+ Ly6G+ cells, suggesting that lal−/− Ly6G+ cells exert proangiogenic effects
on ECs. However, when ECs were co-cultured with macrophages (F4/80+ and CD11b+) that
were isolated from lal+/+ or lal−/− mice, lal+/+ macrophages stimulated tube formation on
ECs, while lal−/− macrophages did not (Figure 5B). This difference indicates differential
abilities between lal+/+ and lal−/− macrophages to stimulate EC tube formation. In a similar
study, both lal+/+ and lal−/− CD4+ T cells showed no effect on EC tube formation (Figure
5B).
In the in vivo matrigel plug assay, matrigel mixed with either lal+/+ or lal−/− Ly6G+ cells
were injected into lal+/+ mice subcutaneously. Fourteen days after implantation, matrigel
plugs containing lal−/− Ly6G+ cells showed more CD31+ cells than those containing lal+/+
Ly6G+ cells. H&E staining results revealed newly formed microvessels in the plugs
containing lal−/− Ly6G+ cells (Figure 5C, see arrows). The effect of Ly6G+ cells on
angiogenesis in vivo was further examined in a B16 melanoma tumor model, a system that
was recently established by us (14). lal+/+ or lal−/− Ly6G+ cells were isolated and mixed
with B16 melanoma cells in matrigel. The mixture was subcutaneously injected into wild
type recipient mice for tumor growth study. IHC staining showed that more CD31+ cells
appeared in matrigel plugs containing lal−/− Ly6G+ cells than those containing lal+/+ Ly6G+
cells (Figure 5D). The underlying mechanism of this proangiogenic activity was further
investigated. The mRNA level of VEGF, a crucial factor in regulating EC angiogenesis, was
up-regulated in lal−/− Ly6G+ cells (Figure 5E). On the other hand, inhibition of VEGF
receptor 2 (VEGFR2) expression by siRNA knockdown in ECs decreased the tube-forming
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activity by lal−/− Ly6G+ cells (Figure 5F), suggesting that VEGF secreted by lal−/− Ly6G+
cells is responsible for the pro-angiogenic activity.
The effect of Ly6G+ cells on EC proliferation was also determined. ECs were co-cultured
with lal+/+ or lal−/− Ly6G+ cells for 72 h, and the numbers of ECs were counted. As shown
in Figure 5G, ECs co-cultured with lal−/− Ly6G+ cells showed more proliferative cells than
those with lal+/+ Ly6G+ cells. lal−/− ECs co-cultured with lal−/− Ly6G+ cells showed the
highest proliferation, which was consistent with Figure 3A, in which proliferation of CD31+
cells was increased in lal−/− mice. This observation was further supported by BrdU
incorporation assay, showing significant increase of BrdU incorporation when ECs were co-
cultured with lal−/− Ly6G+ cells (Figure 5H).
Over-activation of the mTOR pathway is responsible for EC dysfunctions
In lal−/− mice, over-activation of the mTOR pathway has been identified in bone marrow-
derived MDSCs (13, 14, 17). Interestingly, Western blot analysis also detected increased
level of phosphorylated-S6, a downstream target protein of mTOR (41), in lal−/− ECs
(Figure 6A). Knocking down mTOR expression in lal−/− ECs by siRNA transfection showed
significant decrease of phosphorylated-S6 compared with lal−/− ECs transfected with control
siRNA (Figure 6B). These results implied pathogenic roles of mTOR over-activation in
lal−/− ECs. To see if the mTOR pathway plays roles in lal−/− EC dysfunctions, the effect of
mTOR inhibition in lal−/− ECs on Ly6G+ cell transendothelial migration was analyzed by
Transwell assay. After ECs were transfected with mTOR or control siRNA for 48 h, Ly6G+
cells were added to the lal+/+ or lal−/−EC monolayer. Six hours later, the number of Ly6G+
cells in the lower chamber was significantly less across both lal+/+ and lal−/− ECs
transfected with mTOR siRNA than those across ECs with control siRNA transfection
(Figure 6C), suggesting that mTOR inhibition in ECs reduces Ly6G+ cell transendothelial
migration. Furthermore, the in vitro wound healing assay showed delayed migration towards
the scratch in lal−/− ECs with mTOR siRNA transfection at 12 h and 18 h after creating the
scratch, with a significant increase of distance in the wounding area (Figure 6D), indicating
mTOR inhibition impairs the increased migration of lal−/− ECs. Finally, mTOR inhibition in
lal−/− ECs reversed their suppressive activity on T cells. As demonstrated in Figure 6E,
lal−/− ECs with control siRNA transfection showed inhibition on T cell proliferation,
whereas lal−/− ECs with mTOR siRNA transfection displayed reduced inhibition on T cell
proliferation. lal−/− ECs with mTOR siRNA transfection also reversed decreased secretion
of IL-4, IL-10 and IFN-γ by T cells (Figure 6F).
Over-production of ROS mediates the over-activation of mTOR pathway in EC dysfunction
ROS over-production has been observed, and rapamycin treatment decreased the ROS level
in lal−/− Ly6G+ MDSCs (13, 17). Similarly, the ROS level was also increased in lal−/− ECs,
and rapamycin treatment suppressed ROS production in lal−/− ECs (Figure 7A). To see if
the ROS over-production mediates the mTOR signaling in EC dysfunctions, ECs were
treated with antioxidant NAC to neutralize ROS. In the transendothelial migration study,
NAC pre-treatment of ECs significantly reduced both lal+/+ and lal−/− Ly6G+ cell migration
across the ECs monolayer (Figure 7B). The same EC treatment also improved tube
formation of lal−/− ECs (Figure 7C), and delayed lal−/− EC migration towards the scratch
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with a significant increase of distance in the wounding area in the in vitro wound healing
assay (Figure 7D). NAC treatment reduced lal−/− EC proliferation (Figure 7E). Finally,
NAC pre-treatment of lal−/− ECs reversed their suppressive activity on T cell proliferation
(Figure 7F). Taken together, these results support a concept that ROS over-production
serves as a mechanism mediating mTOR over-activation in lal−/− EC dysfunctions.
Discussion
LAL is a key enzyme in the metabolic pathway of neutral lipids, and the relationship
between LAL and inflammation has been well documented (1, 10-14, 28). Genetic ablation
of the lal gene in mice has resulted in a systemic increase of MDSCs, causing severe
inflammation and pathogenesis in multiple organs (10). ECs, the major components of blood
vessels, are actively involved in inflammation and many other pathogenic conditions.
However, the effects of LAL deficiency on EC functions remain to be explored. The major
new findings of the present study were that LAL deficiency in ECs 1) enhanced the
transendothelial migration of MDSCs, with a concomitant increase of PECAM-1 and
ICAM-2 protein levels, 2) impaired in vitro tube-forming capability and in vivo
angiogenesis, but increased migration, 3) facilitated cell proliferation, paralleled with
reduced apoptosis, and 4) suppressed T cell proliferation and function. The potential
mechanisms underlying EC dysfunction were identified, including the interaction with
MDSCs, intrinsic over-activation of the mTOR pathway, and cellular overproduction of
ROS. lal−/− MDSCs were found to increase transmigration across EC monolayers, promote
in vivo angiogenesis, and EC tube formation and proliferation. The mTOR pathway was
over-activated in lal−/− ECs, and inhibition of mTOR in lal−/− ECs partially reversed their
dysfunctions, including reducing transmigration of MDSCs, EC migration, and suppression
of T cell proliferation and function, which was mediated by decreasing ROS production.
Transendothelial migration of leukocytes, or diapedesis, is a critical step in the inflammatory
response. The preceding steps of leukocyte rolling, activation, adhesion, and locomotion are
all reversible. However, once the leukocytes commit to diapedesis, they do not return to the
circulation, at least not as the same cell type (27, 42). Recent studies have shown that
transendothelial migration was promoted by multiple endothelium-derived inflammatory
chemokines (43, 44). Because we previously observed increased MDSC accumulation in the
lungs of lal−/− mice (1, 10, 12), we hypothesized that LAL deficiency in ECs would enhance
transendothelial migration of MDSCs. In consistence with our hypothesis, MDSCs migrated
more efficiently across lal−/− ECs than lal+/+ ECs. In addition, lal−/− MDSCs showed a
greater transmigration capability than that of lal+/+ MDSCs (Figure 1A). There was a more
than 3-fold increase in the transmigration of lal−/− MDSCs across lal−/− ECs than that of
lal+/+ MDSCs across lal+/+ ECs, which mimicked the pathological condition of lal−/− mice.
Our finding demonstrated that in lal−/− mice, not only myeloid cells but also pulmonary ECs
contribute to the increased transendothelial migration, which may explain the increased
accumulation of myeloid cells in the bronchoalveolar lavage fluid of lal−/− mice (10).
Several mechanisms are involved in the process of transendothelial migration, among which
is the hemophilic interaction of leukocyte PECAM with endothelial PECAM (27).
PECAM-1 is an immunoglobulin superfamily member concentrated at the borders of ECs,
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as well as diffusely on platelets and leukocytes. Study has shown that when PECAM-
PECAM interactions are blocked, leukocytes are arrested tightly adherent to the apical
surface of the cell (27, 45). In the present study, we found that PECAM-1 protein level was
increased in lal−/− ECs (Figure 1C) and inhibition of PECAM-1 in ECs by siRNA
transfection or neutralizing antibodies led to reduced transendothelial migration of lal−/−
MDSCs (Figure 1D-E), which were consistent with previous findings, suggesting that the
elevated expression of PECAM-1 in lal−/− ECs is critical for the enhanced transendothelial
migration. We also found that ICAM-2 protein level was increased in lal−/− ECs, whose
deletion has been reported to inhibit transmigration of neutrophils (46, 47). In addition to
adhesion molecules in facilitating transendothelial migration of leukocytes, chemokines play
an important role in recruiting monocytes, neutrophils, and lymphocytes to the vascular
endothelium. MCP-1, acting through its receptor CCR2, has been demonstrated to recruit
monocytes into foci of inflammation (48). The increased level of MCP-1 in lal−/− ECs and
CCR2 in lal−/− Ly6G+ cells was observed (Figure 1F-G). Pre-treatment of ECs with anti-
MCP-1 neutralizing antibodies reduced Ly6G+ cell transmigration by about 50% (Figure
1H). Furthermore, increased production of cytokines IL-6 and TNFα in lal−/− ECs has been
observed, and combination of all three neutralizing antibodies further blocked Ly6G+ cell
transmigration (Figure 1F and 1H), demonstrating up-regulated production of chemokines
and cytokines in lal−/− ECs is responsible for mediating Ly6G+ cell transendothelial
migration.
Angiogenesis, the growth of new capillaries from preexisting blood vessels, is a feature of
chronic inflammation. ECs are the principle cell population participating in this complex
process, which involves EC activation, disruption of vascular basement membranes,
migration and proliferation of ECs, and the subsequent formation and maturation of blood
vessels (49). Failure of ECs to adequately perform their angiogenesis-related functions
would lead to an imbalance of the angiogenic process, resulting in the pathogenesis of
numerous disorders (50). An important aspect of angiogenesis involves the organization of
ECs into three-dimensional tube-like structures. Our results showed that LAL deficiency
enhanced EC migration (Figure 2D), impaired EC tube formation (Figure 2A), and
decreased in vivo angiogenesis by matrigel plug assay (Figure 2B-C).
During the process of angiogenesis, EC proliferation is required to provide the necessary
number of cells for new blood vessel formation (51). However, increased EC proliferation is
often related to pathological conditions. In lal−/− mice, it seems that both intrinsic defects
and environmental factors contribute to EC proliferation. We observed that there were more
pulmonary CD31+ cells, with significantly decreased apoptosis (Figure 3A and 3D). After in
vitro culture, lal−/− ECs showed enhanced proliferation (Figure 3B-C). Furthermore, EC
proliferation was greatly increased in the presence of plasma harvested from lal−/− mice.
lal−/−ECs co-cultured with plasma from lal−/− mice, a mimic of the in vivo situation of lal−/−
mice, showed the greatest proliferation compared with other groups (Figure 3E), which was
in agreement with the in vivo observation that more CD31+ cells existed in the lungs of
lal−/− mice (Figure 3A). In addition, the up-regulated expression of VEGFR2 in lal−/− ECs
was responsible for their higher response to the environmental factors since VEGFR2
knockdown in lal−/− ECs impaired the stimulatory effect of lal−/− plasma on their
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proliferation (Figure 3 F-G). Collectively, the above observations suggest that LAL
deficiency facilitates EC proliferation and inhibits EC apoptosis, despite the fact that lal−/−
ECs had a poor capability of tube formation (Figure 2A) and in vivo capillary formation
(Figure 2B).
ECs, which form the interface between the blood and the underlying tissue, are uniquely
positioned for frequent contact with circulating T cells (23). In lal−/− mice, impairment in T
cell proliferation and function has previously been reported (28). A recent study has found
that direct cell-cell contact between ECs and T cells is required for EC-induced T cell
proliferation (40). In our study, lal−/− ECs showed inhibition on T cell proliferation and
lymphokine secretion (Figure 4), which is an additional cellular mechanism of the impaired
T cell proliferation in lal−/− mice.
In lal−/− mice, one major manifestation is the massive expansion and infiltration of MDSCs
into multiple organs (1, 2, 10, 12, 52). Therefore, we speculate that MDSCs from lal−/− mice
interact with ECs and influence ECs’ functions. Previously, MDSCs isolated from mouse
tumors have been reported to induce in vitro angiogenesis by tube formation assay via
producing angiogenic factors, including VEGF and bFGF (9). In the present study, we found
that the tube-forming capability of lal−/− ECs was increased after co-culturing with lal−/−
MDSCs (Figure 5A), and the pro-angiogenic effects of lal−/− MDSCs was mediated by
increased production of VEGF (Figure 5E-F), suggesting that lal−/− MDSCs had the similar
pro-angiogenic effects as tumor-derived MDSCs. The in vivo matrigel plug assay further
confirmed the pro-angiogenic activity of lal−/− MDSCs (Figure 5C-D). Therefore, in lal−/−
mice, compared with ECs’ intrinsic angiogenic defect, the pro-angiogenic activity of lal−/−
MDSCs contribute to the angiogenesis required for the process of inflammation. lal−/−
MDSCs also facilitated EC proliferation (Figure 5C-D), which explains why more CD31+
cells existed in the lungs of lal−/− mice (Figure 3A). Taken together, MDSC expansion
contributes to EC dysfunctions in lal−/− mice.
The mTOR pathway is a key regulator of cell growth and proliferation. Increasing evidence
suggests that its dysregulation is associated with human diseases, including metabolic
disease, neurodegeneration, aging, cancer, diabetes, and cardiovascular disease (53, 54).
mTOR, defined as a regulatory kinase in ECs, plays an important role in EC survival,
migration, and proliferation, and PI3K/AKT/mTOR signaling pathway may regulate
PECAM-1 expression in mEC/EB derived ECs (16, 55). In the present study, we found that
the phosphorylation level of mTOR downstream target S6 was significantly increased in
lal−/− ECs, which can be reversed after mTOR knocking down by siRNA transfection.
Knocking down mTOR in lal−/− ECs partially reversed EC dysfunctions, including
decreasing the enhanced transmigration of MDSCs across lal−/− ECs, impairing the
increased lal−/− ECs migrating capability and proliferation, and relieving the lal−/− ECs
suppression on T cell proliferation and function (Figure 6C-F). We have recently reported
that over-activation of the mTOR signaling leads to ROS over-production in lal−/− MDSCs
(13). In the present study, ROS over-production was also observed in lal−/− ECs, which was
reduced by mTOR inhibitor rapamycin. Neutralization of ROS by antioxidant NAC in lal−/−
ECs reversed their dysfunctions (Figure 7), similar to those observed in mTOR studies.
Therefore, ROS over-production serves as a major mechanism to mediate the mTOR
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pathway in EC dysfunctions. The above findings provide a mechanistic basis for targeting
MDSCs or mTOR or ROS to rejuvenate EC functions in LAL deficiency-related diseases.
Clinically, LAL deficiency results in inherited recessive in-born error metabolic diseases:
Wolman disease as the infantile on-set and cholesteryl ester storage disease (CESD) as the
late on-set. Our lal−/− mice represent Wolman disease biochemically and CESD
physiologically. Both enzyme therapy using recombinant human LAL (hLAL) protein and
gene therapy using adenovirus-mediated hLAL expression have been successfully tested in
lal−/− mouse model (56-58). It is conceivable that these strategies can be used to treat EC
dysfunctions. In summary, our studies strongly support a concept that neutral lipid
metabolism controlled by LAL plays a critical role in maintaining ECs’ normal functions by
regulation of MDSCs and the mTOR pathway.
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Figure 1. LAL deficiency in ECs leads to increased transendothelial migration of Ly6G+ cells
(A) Transwell assay was performed to determine Ly6G+ cells transmigration across the
endothelial monolayer formed by lal+/+ or lal−/− ECs. Six hours after seeding Ly6G+ cells
on the EC monolayer, the number of Ly6G+ cells that have migrated to the lower chamber
was counted. Bars represent 250 μm. (B) CD4+ T cell transmigration across the endothelial
monolayer formed by lal+/+ or lal−/− ECs was examined. Six hours later, the number of
transmigrating CD4+ T cells was counted. (C) Expressions of PECAM-1 and ICAM-2 in
ECs were determined by Western blot analysis. β-actin was used as control. Representative
blots of 4 individual experiments were shown. (D) Transwell assay was performed to
determine Ly6G+ cells transmigration across the ECs that were transfected with PECAM-1
siRNA; (E) Transwell assay was performed to determine Ly6G+ cells transmigration across
the ECs that were pre-treated with anti-PECAM-1 neutralizing antibodies or control IgG; (F)
Real-time PCR analysis of mRNA expression levels of MCP-1, IL-6 and TNFα in lal+/+ vs.
lal−/− ECs. The relative gene expression was normalized to GAPDH mRNA, and analysis
was performed by the 2−ΔΔCT method. (G) Real-time PCR analysis of mRNA expression
level of CCR2 in lal+/+ vs. lal−/− Ly6G+ cells. The relative gene expression was normalized
to GAPDH mRNA, and analysis was performed by the 2−ΔΔCT method. (H) To block
chemokines and cytokines, ECs were pre-treated with 10 μg/mL neutralizing antibody
against MCP-1, IL-6, TNF-α individually or in combination, or control IgG for 1 h. Six
hours after seeding Ly6G+ cells on the EC monolayer, the number of migrating Ly6G+ cells
was counted. In all above experiments, data were expressed as mean ± SD; n = 4. *P < 0.05,
**P < 0.01.
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Figure 2. LAL deficiency influences EC angiogenic functions
(A) In vitro matrigel tube formation was performed to compare the tube-forming capability
between lal+/+ and lal−/− ECs. Top: representative micrographs of matrigel tube formation
in ECs from lal+/+ and lal−/− mice at different time interval. Bottom: statistical analysis of
cumulative tube lengths at 6 h. Data were normalized to lal+/+ ECs and expressed as mean
±SD; n = 4. *P < 0.05. (B) In vivo angiogenesis was assessed by matrigel plug assay.
Matrigel plugs containing ECs isolated from lungs of lal+/+ or lal−/− mice were implanted
into lal+/+ mice. Plugs were harvested for H&E and immunohistochemical staining 10 d
after implanting in vivo. Representative microphotographs of matrigel plug sections stained
with H&E and CD31 antibody were shown. Original magnification ×400. (C) Perfusion of
matrigel plugs was determined by measuring the hemoglobin content. Data were normalized
to lal+/+ ECs and expressed as mean ±SD; n = 4, **P < 0.01; (D) The in vitro wound healing
assay was conducted to determine EC migration in the presence of mitomycin C. Left:
Representative pictures of wound healing assay of ECs from lal+/+ or lal−/− mice at the
beginning and end of incubation (0 and 15h, respectively). The dotted lines define the areas
lacking cells. Right: Quantification of distance from one end to the other end of the wound
area. Data were normalized to lal+/+ ECs at 0 h and expressed as mean ±SD; n = 4. *P <
0.05, **P < 0.01. Bars represent 500 μm.
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Figure 3. LAL deficiency facilitates EC proliferation
(A) Comparison of the number of CD31+ cells in the lungs of lal+/+ or lal−/− mice. Lung
cells from lal+/+ or lal−/− mice were purified by anti-CD31 microbeads and counted. (B)
ECs after 3 days’ culture were harvested, and the number was compared between lal+/+ and
lal−/− mice. (C) The percentage of BrdU incorporation into lal+/+ or lal−/− ECs were
analyzed by flow cytometry. (D) The percentage of Annexin V positive cells in lung CD31+
cells from lal+/+ or lal−/− mice. (E) ECs were cultured in medium containing 20% plasma
from lal+/+ or lal−/− mice for 72 h, and the cell number was counted afterwards. (F) Flow
cytometry analysis of VEGFR2 expression in lal+/+ vs. lal−/− ECs. Data were normalized to
lal+/+ ECs. (G) ECs transfected with VEGFR2 or control siRNA were cultured in medium
containing 20% plasma from lal+/+ or lal−/− mice for 72 h, and the cell number was counted
afterwards. In all above experiments, data were expressed as mean ± SD; n = 3-4. *P < 0.05,
**P < 0.01.
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Figure 4. ECs from lal−/− mice suppress T cell proliferation and function
(A) CFSE-labeled lal+/+ CD4+ T cells were stimulated with anti-CD3 mAb plus anti-CD28
mAb for 4 days in the presence or absence of ECs from the lungs of lal+/+ or lal−/− mice at
10:1 ratio between CD4+ T cells: ECs. The proliferation of labeled CD4+ T cells was
analyzed by flow cytometry. Peaks represent cell division cycles. PBS was used as a
negative control. (B) The secretions of IL-4, IFN-γ, IL-10, and IL-17 of CD4+ T cells in the
culture medium were measured by ELISA analysis. Data were expressed as mean ± SD; n =
3~4. **P < 0.01.
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Figure 5. Ly6G+ cells from lal−/− mice influence EC functions
(A) The effect of Ly6G+ cells on EC tube-forming capability was determined by matrigel
tube formation assay. Left: representative micrographs of tube formation in ECs co-cultured
with lal+/+ or lal−/− Ly6G+ cells. Right: statistical analysis of cumulative tube lengths. Data
were normalized to lal+/+ ECs only. Bars represent 500 μm. (B) The effects of macrophages
(F4/80+ and CD11b+) and CD4+ T cells on EC tube-forming capability were determined by
matrigel tube formation assay. (C) The effect of Ly6G+ cells on angiogenesis in the in vivo
matrigel plug assay. Matrigel plugs containing Ly6G+ cells isolated from bone marrow of
lal+/+ or lal−/− mice were implanted into lal+/+ mice. Plugs were harvested 14 d after
implantation and analyzed by H&E and immunohistochemical staining. Representative
microphotographs of matrigel plug sections stained with H&E and CD31 antibody were
shown. Original magnification ×200. (D) The effect of Ly6G+ cells on angiogenesis in the
B16 melanoma tumor model. Matrigel mixed with B16 melanoma cells (1× 105) and lal+/+
or lal−/− Ly6G+ cells (1× 106) was implanted subcutaneously into lal+/+ mice for 10 days.
Representative microphotographs of matrigel plug sections stained with CD31 antibody
were shown. Original magnification ×200. n=10. (E) Real-time PCR analysis of the mRNA
expression level of VEGF in lal+/+ vs. lal−/− Ly6G+ cells. The relative gene expression was
normalized to GAPDH mRNA, and determined by the 2−ΔΔCT. (F) ECs were transfected
with VEGFR2 or control siRNA, and then the effect of Ly6G+ cells on EC tube-forming
capability was determined by matrigel tube formation assay. Statistical analysis of
cumulative tube lengths was shown. Data were normalized to lal+/+ ECs only. (G) ECs after
3 days’ co-culture with lal+/+ or lal−/− Ly6G+ cells were harvested, and the number was
counted. (H) The percentage of BrdU incorporation into lal+/+ or lal−/− ECs co-cultured with
Zhao et al. Page 23













Ly6G+ cells was analyzed by flow cytometry. In above experiments, data were expressed as
mean ± SD; n = 3-4. *P < 0.05, **P < 0.01.
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Figure 6. Activation of the mTOR pathway is involved in EC dysfunctions
(A) Expressions of phosphorylated-S6 and S6 in lal+/+ or lal−/− ECs were determined by
Western blot analysis. Representative blots of 4 individual experiments were shown. (B)
After inhibition of mTOR in ECs by siRNA transfection, the expressions of phosphorylated-
S6 and S6 were examined afterwards. Representative blots of 3 individual experiments were
shown. (C) Ly6G+ cells transmigration was determined after mTOR knockdown by siRNA
transfection in ECs. Data were normalized to lal+/+ Ly6G+ cells transmigrating across lal+/+
ECs with control siRNA (C siRNA) transfection and expressed as mean ± SD; n = 4-5. *P <
0.05, **P < 0.01. (D) EC migration after mTOR knockdown was assessed by in vitro wound
healing assay in the presence of mitomycin C. Data were normalized to lal+/+ ECs with
control siRNA transfection at 0 h and expressed as mean ± SD; n = 3. *P < 0.05, **P < 0.01.
Bars represent 250 μm (C) and 500 μm (D). (E) Proliferation of CFSE-labeled lal+/+ CD4+ T
cells in the presence or absence of lal+/+ or lal−/− ECs with mTOR or control siRNA
transfection was analyzed by flow cytometry. (F) The secretion of IL-4, IL-10 and IFN-γ of
CD4+ T cells in the culture medium was measured by ELISA analysis. Data were expressed
as mean ± SD; n = 4. *P < 0.05, **P < 0.01.
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Figure 7. ROS over-production causes EC dysfunctions
(A) ROS production was increased in lal−/− ECs, which was reversed by mTOR inhibitor
rapamycin. Statistical analysis of mean fluorescent intensity (MFI) of the ROS level by flow
cytometry is shown. (B) Ly6G+ cell transmigration was determined after antioxidant NAC
pre-treatment of ECs. (C) Tube formation of ECs after NAC pre-treatment. Data were
normalized to lal+/+ ECs. (D) EC migration after NAC treatment by in vitro wound healing
assay at 15h in the presence of mitomycin C. Data were normalized to lal+/+ ECs at 0 h. (E)
EC proliferation after NAC treatment. (F) The proliferation of lal+/+ CD4+ T cells in the
presence of lal+/+ or lal−/− ECs with or without NAC pre-treatment was analyzed by flow
cytometry. In all above experiments, data were expressed as mean ± SD; n = 4. *P < 0.05,
**P < 0.01.
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